TABLE 3.
Dose constraints for high‐risk patients with prostate cancer.
| Structure name | Optimal | Tolerable | |
|---|---|---|---|
| PTV–Rectum–UrethraPRV | D98% | >34.448 Gy | >32.625 Gy |
| Dmax | <43.2 Gy | ||
| D95% | >36.25 Gy | ||
| PTV/rectum | D98% | >34 Gy | >32.625 Gy |
| Rectum | V36.0 Gy | <1 cc | |
| V32.6 Gy | <15% | ||
| V29 Gy | <20% | ||
| V25.3 Gy | <30% | ||
| V21.7 Gy | <40% | ||
| V18.1 Gy | <50% | ||
| Bladder | V18.1 Gy | <40% | |
| V37.0 Gy | <5 cc | <10 cc | |
| UrethraPRV | Dmax | <40 Gy | |
| Femur head | V14.5 Gy | <5% | |
| Dmax | <25.375 Gy | ||
| CTV−UrethraPRV | D95% | >100% | >98% |
Abbreviations: CTV, clinical target volume; CTV−UrethraPRV, CTV minus urethraPRV; Dmax, maximal dose; D95%, dose administered to 95% of volume; D98%, dose administered to 98% of volume; PRV, planning organ at risk volume; PTV, planning target volume; PTV−Rectum−UrethraPRV, PTV minus rectum minus urethraPRV; PTV/rectum, common area of PTV and rectum.